AstraZeneca shareholders have approved the company's 2024 pay policy, providing a significant boost to CEO Soriot. The decision was made during the Annual General Meeting (AGM) of AstraZeneca, where shareholders voted in favor of the proposed pay policy.
The approval of the 2024 pay policy indicates confidence in the leadership of CEO Soriot and the company's future direction. This move is seen as a positive development for AstraZeneca, as it demonstrates support for the executive team and their strategic vision.